Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Bone Neoplasms

lenalidomide has been researched along with Bone Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Yazici, G; Yuce Sari, S1
Kirova, Y; Mignot, F1
Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L1
Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E1
Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS1
Jung, W; Schroers, R; Zettl, F1

Other Studies

6 other study(ies) available for lenalidomide and Bone Neoplasms

ArticleYear
In Regard to Mignot et al.
    International journal of radiation oncology, biology, physics, 2020, 04-01, Volume: 106, Issue:5

    Topics: Bone Neoplasms; Dexamethasone; Humans; Lenalidomide; Plasmacytoma

2020
In Reply to Sari and Yazici.
    International journal of radiation oncology, biology, physics, 2020, 04-01, Volume: 106, Issue:5

    Topics: Bone Neoplasms; Dexamethasone; Humans; Lenalidomide; Plasmacytoma; Tumor Suppressor Proteins

2020
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
    Annals of hematology, 2017, Volume: 96, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous

2017
A case of multiple myeloma with navicular bone involvement.
    Scottish medical journal, 2017, Volume: 62, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Osteolysis; Plasma Cells; Remission Induction; Stem Cell Transplantation; Tarsal Bones; Thalidomide

2017
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure

2012
[Multiple myeloma -- therapy].
    Deutsche medizinische Wochenschrift (1946), 2005, Feb-11, Volume: 130, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2005